RTTNews BiotechDoubao · 实盘不做把握 8/10不做原因:无增量信息
北京时间·🕒 发布 15:56:56(美东 03:56)·⟳ 抓取 16:00:59 +4m03s·⚡ 决策 10-26 16:03:08 +2m09s·23.8 小时前
罗氏 divarasib 三期 Krascendo 1 头对头优效、死亡风险降44%，但系旧数据被 RTTNews 重述
同一 divarasib Krascendo 1 催化在过去约12小时内已由本臂三度判定不做：三期顶线2026-07-02已正式公告、Q2已上调峰值指引，完整OS/PFS数据2026-10-25已在ESMO主席研讨会公布并同步NEJM；本条RTTNews仅为英文媒体重述，无任何新增金额、监管进展或指引修正。直接标的罗氏为超大盘药企、软催化相对市值增量小且OTC/SIX无可执行行情；竞品安进/BMS利空旧、占比小，周一盘前无事件级异动，做多做空均无正期望。
📄 原文RTTNews Biotech↗ 原文
Roche's Divarasib Cuts Death Risk By 44% In Phase 3 KRAS G12C-Mutated Lung Cancer Study
Genentech, a member of the Roche Group (RHHBY), announced pivotal results from the Phase 3 Krascendo 1 study, which sho…
不做 罗氏 Roche（OTC ADR）（RHHBY.US）
旧催化重述、无新增事实且已price-in（顶线07-02、完整数据10-25 ESMO/NEJM）；超大盘药企单一管线软催化对市值增量小，OTC ADR流动性差/SIX主板无可靠行情，无法定价执行。
不做 安进 Amgen（AMGN.US）
sotorasib竞品利空在数据首发窗口已消化、占安进市值比重小；本条无新增负面事实，周一盘前仅微幅无量波动，做空不满足新鲜强催化，无edge。
不做 百时美施贵宝 BMS（BMY.US）
adagrasib同为对照竞品但利空旧、营收占比低，本条无新增边际信息，不构成可交易做空机会。
展开详情(成交明细 / 研究档案 / 原文全文 / 决策记录链)
研究档案
结论摘要
divarasib 头对头 OS/PFS 双优效是真实医学利好，但顶线7月已公告、完整数据10-25 ESMO/NEJM已落地并price-in，RTTNews本条无新增事实；罗氏市值弹性小且无可靠盘中行情，安进/BMS竞品利空亦旧，无可交易edge，故回避。
消息传播链
- RTTNews重述10-25 ESMO/NEJM完整数据，未含任何新增事实、指引或监管节点；属同一催化的二手扩散。市场反应:安进AMGN.US周一盘前价格约441.65美元、仅+0.5%、量极低（270股），无事件级冲击。
关键理由
- 对罗氏：best-in-class 的 KRAS G12C 三期 OS HR 0.56 支撑其峰值销售与SOC潜力，但该预期自07-02顶线及Q2指引上调以来已被市场计入。
- 对安进/BMS：sotorasib/adagrasib作为对照组疗效落后，长期份额承压，但利空在数据首发窗口已消化，本条重述不带来新的边际重定价。
主要风险
- 若罗氏借完整数据于2026-10-26另行上调指引或宣布加速申报/合作，将构成新增事实，需重新研判（当前未见）。
- 周一美股开盘后安进/BMS若出现与本旧闻无关的异常放量下杀，应区分新信息而非据本条追空。
反向证据
- 做多前查反向 · 来源 web · 日期 2026-10-26 · 影响 supports
未发现10-26新增的指引上调、监管申报或商业授权；ESMO/NEJM后无进一步边际利好。
检索:Roche divarasib 2026-10-26 guidance upgrade filing approval new 原文 ↗ - 做空前查反向 · 来源 web · 日期 2026-10-26 · 影响 supports
竞品利空在07-02/10-25首发窗口已被讨论，周一盘前AMGN仅微涨、无量，无新增下杀证据，做空无fresh edge。
检索:Amgen Lumakras sotorasib divarasib Krascendo market reaction October 2026 原文 ↗
先例如何影响了这次决策
对本次决策的影响:确认回避，未改变标的或方向。
方向:本条因查重命中同一具体催化且无新增事实而早停，未再跑外部先例；本臂前序两度对该催化的AVOID结论已覆盖定价判断。
涨幅量级:不适用：无新增边际事件，无需用先例校准tp/sl。
形态:不适用：不入场。
工具执行结果 · 成功 3 · 降级 1 · 失败 0 · 取消 0
- search_processed_events 成功 stock_tools HTTP · 176 ms
{"result": "search_processed_events:agent query=`divarasib sotorasib adagrasib head-to-head os 44% death risk reduction | roche genentech divarasib phase 3 krascendo 1 kras g12c lung cancer | 罗氏 divarasib 三期 kras g12c 非小细胞肺癌`；结构化索引覆盖完整 72 小时；旧记录兼容扫描近 71.7/72 小时、1753 条本臂决策(完整)，返回 3 条候选。\n• 10-26 03:3 - web_search 成功 doubao_search · 2,941 ms
豆包搜索结果（原始查询:Roche divarasib Krascendo 1 Phase 3 KRAS G12C NSCLC results overall survival；API SearchType:web） - stock_quote 成功 stock_tools HTTP · 126 ms
裸代码无法确定市场(证券列表只含股票，不含 ETF/基金)。请带市场后缀再查，如 EIDO.US、2800.HK、510300.SH。 - stock_quote 降级 stock_tools HTTP · 52 ms
{
原文全文
展开原文 · 2,772 字
Genentech, a member of the Roche Group (RHHBY), announced pivotal results from the Phase 3 Krascendo 1 study, which showed superior efficacy of investigational divarasib compared with the current standard-of-care KRAS G12C inhibitors in people with previously treated KRAS G12C-mutated non-small cell lung cancer (NSCLC).
Divarasib is an investigational next-generation oral KRAS G12C inhibitor. The Phase III Krascendo 1 trial is a head-to-head study comparing divarasib with approved first-generation KRAS G12C inhibitors.
Trial Details
The study enrolled 338 adults who were randomised to receive either once-daily divarasib (n=167) or a control KRAS G12C inhibitor, consisting of once-daily sotorasib or twice-daily adagrasib (n=171).
The primary endpoint was progression-free survival (PFS) assessed by blinded independent central review (BICR).
Key secondary endpoints included overall survival (OS), confirmed objective response rate (ORR), duration of response (DoR), and additional efficacy and safety measures.
Key Findings
The study met its primary and key secondary endpoints, with divarasib demonstrating statistically significant and clinically meaningful improvements in both PFS and OS compared with sotorasib or adagrasib.
Participants treated with divarasib monotherapy experienced a 44% reduction in the risk of death compared with those receiving sotorasib or adagrasib (HR=0.56; 95% CI: 0.41-0.78; p=0.0005). Median OS was approximately 18 months with divarasib versus 12 months in the control arm.
The OS and PFS benefit was consistent across clinically relevant subgroups, and was observed regardless of PD-L1 expression or KEAP1 mutation status.
The objective response rate (ORR) with divarasib was nearly double that of sotorasib or adagrasib.
The safety profile of divarasib monotherapy was consistent with the known class effects of KRAS G12C inhibitors.
"The Phase III Krascendo 1 results demonstrate the potential for divarasib to become a new standard of care for people with previously treated KRAS G12C-mutated lung cancer," said Levi Garraway, chief medical officer and head of Global Product Development.
Stock Performance
RHHBY has traded between $301.27 and $514.08 over the last year. The stock closed Friday's (October 23, 2026) trade at $492.81, up 2.67%.
For more biotech stock news, visit www.rttnews.com
For comments and feedback contact: editorial@rttnews.com
Business News
October 16, 2026 16:06 ET Monthly consumer price inflation data and retail sales figures were the main news from the U.S. economy this week. In Europe, monthly GDP figures from the U.K. gained attention. External trade data from China was in focus in Asia. Elsewhere, the International Monetary Fund released its latest projections for the global economy.
Divarasib is an investigational next-generation oral KRAS G12C inhibitor. The Phase III Krascendo 1 trial is a head-to-head study comparing divarasib with approved first-generation KRAS G12C inhibitors.
Trial Details
The study enrolled 338 adults who were randomised to receive either once-daily divarasib (n=167) or a control KRAS G12C inhibitor, consisting of once-daily sotorasib or twice-daily adagrasib (n=171).
The primary endpoint was progression-free survival (PFS) assessed by blinded independent central review (BICR).
Key secondary endpoints included overall survival (OS), confirmed objective response rate (ORR), duration of response (DoR), and additional efficacy and safety measures.
Key Findings
The study met its primary and key secondary endpoints, with divarasib demonstrating statistically significant and clinically meaningful improvements in both PFS and OS compared with sotorasib or adagrasib.
Participants treated with divarasib monotherapy experienced a 44% reduction in the risk of death compared with those receiving sotorasib or adagrasib (HR=0.56; 95% CI: 0.41-0.78; p=0.0005). Median OS was approximately 18 months with divarasib versus 12 months in the control arm.
The OS and PFS benefit was consistent across clinically relevant subgroups, and was observed regardless of PD-L1 expression or KEAP1 mutation status.
The objective response rate (ORR) with divarasib was nearly double that of sotorasib or adagrasib.
The safety profile of divarasib monotherapy was consistent with the known class effects of KRAS G12C inhibitors.
"The Phase III Krascendo 1 results demonstrate the potential for divarasib to become a new standard of care for people with previously treated KRAS G12C-mutated lung cancer," said Levi Garraway, chief medical officer and head of Global Product Development.
Stock Performance
RHHBY has traded between $301.27 and $514.08 over the last year. The stock closed Friday's (October 23, 2026) trade at $492.81, up 2.67%.
For more biotech stock news, visit www.rttnews.com
For comments and feedback contact: editorial@rttnews.com
Business News
October 16, 2026 16:06 ET Monthly consumer price inflation data and retail sales figures were the main news from the U.S. economy this week. In Europe, monthly GDP figures from the U.K. gained attention. External trade data from China was in focus in Asia. Elsewhere, the International Monetary Fund released its latest projections for the global economy.
决策记录链 · 只追加
每次领取产生一条记录,重新决策追加一条并以 supersedes 指向被替代的记录(ADR 0014)。
cf8bcf65c9· 2026-10-26 16:03 · doubao / doubao-seed-evolving-latest-version · 策略包b7b4acf827b8当前